Concepedia

Molly Catherine Hardebeck

MC

9

Publications

1.3K

Citations

9

H-Index

2013

Active since

Affiliations

Eli Lilly (United States)(Current)

Hospital General Universitario Gregorio Marañón

The University of Texas Southwestern Medical Center

Mayo Clinic in Arizona

Stanford University

Molly Catherine Hardebeck is an author at Eli Lilly (United States) specializing in medicine, genome instability, and molecular biology.

ORCID

Top concepts

Publications per year

2013–2021

9

Publications

9

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Stephen Johnston, Miguel Martín, Angelo Di Leo et al. · npj Breast Cancer · 2019 · 650 citations · Full text

Phosphorylation of EXO1 by CDKs 1 and 2 regulates DNA end resection and repair pathway choice

Nozomi Tomimatsu, Bipasha Mukherjee, Molly Catherine Hardebeck et al. · Nature Communications · 2014 · 179 citations · Full text

, , +8

Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

Carlos R. Gil Del Alcazar, Molly Catherine Hardebeck, Bipasha Mukherjee et al. · Clinical Cancer Research · 2013 · 168 citations · Full text

DNA-damage-induced degradation of EXO1 exonuclease limits DNA end resection to ensure accurate DNA repair

Nozomi Tomimatsu, Bipasha Mukherjee, Janelle L. Harris et al. · Journal of Biological Chemistry · 2017 · 77 citations · Full text

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

Stephen Johnston, Joyce O’Shaughnessy, Miguel Martín et al. · npj Breast Cancer · 2021 · 59 citations · Full text

Rows per page

1–5 of 9